Breast-conserving therapy for Stage I-II synchronous bilateral breast carcinoma

Smitha Valli Gollamudi, Rebecca S. Gelman, Gloria Peiro, Lindsey J. Schneider, Stuart J. Schnitt, Abram Recht, Barbara J. Silver, Jay R. Harris, James L. Connolly

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Synchronous bilateral breast carcinoma (SBBC) is an uncommon presentation, and the management of patients with this disease is not well established. METHODS. In order to evaluate whether patients with early-stage SBBC could be safely and effectively treated with bilateral breast-conserving therapy (BCT), the authors retrospectively reviewed the records of 24 patients with clinical Stage I-II SBBC treated during the period 1977-1989 with bilateral BCT. SBBC was defined as bilateral invasive carcinomas diagnosed no more than 1 month apart. The median age at diagnosis was 56 years (range, 32-85-years), and the median follow-up for surviving patients was 95 months (range, 68-157 months). Pathology slides were available for review in 19 cases. Cosmetic results and complications after BCT were scored. Outcome was compared with that of 1314 patients with unilateral Stage I or II breast carcinoma, within the same age range, treated during the same time period. RESULTS. There were no significant differences between the SBBC and unilateral groups in actuarial disease free survival (70% and 74%, respectively, at 5 years), overall survival (88% and 87%, respectively, at 5 years), or crude distribution of sites of first failure. Multivariate analysis of overall survival and disease free survival also did not show bilaterality to be a significant factor. The cosmetic results for the SBBC group were not significantly different from those for the unilateral group. Physician assessment of cosmetic outcome was excellent in 57% and good in 43% of SBBC patients evaluated 25-48 months after BCT. Long term complications were rare in both groups. CONCLUSIONS. Patients with early-stage SBBC can be safely treated with carefully planned, bilateral BCT, with outcome that appears to be comparable to that of patients with early-stage unilateral breast carcinoma.

Original languageEnglish (US)
Pages (from-to)1362-1369
Number of pages8
JournalCancer
Volume79
Issue number7
DOIs
StatePublished - Apr 1 1997
Externally publishedYes

Fingerprint

Breast
Breast Neoplasms
Cosmetics
Therapeutics
Disease-Free Survival
Survival
Multivariate Analysis
Outcome Assessment (Health Care)
Pathology
Carcinoma
Physicians

Keywords

  • adenocarcinoma
  • bilateral
  • breast neoplasms
  • radiotherapy
  • synchronous

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gollamudi, S. V., Gelman, R. S., Peiro, G., Schneider, L. J., Schnitt, S. J., Recht, A., ... Connolly, J. L. (1997). Breast-conserving therapy for Stage I-II synchronous bilateral breast carcinoma. Cancer, 79(7), 1362-1369. https://doi.org/10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y

Breast-conserving therapy for Stage I-II synchronous bilateral breast carcinoma. / Gollamudi, Smitha Valli; Gelman, Rebecca S.; Peiro, Gloria; Schneider, Lindsey J.; Schnitt, Stuart J.; Recht, Abram; Silver, Barbara J.; Harris, Jay R.; Connolly, James L.

In: Cancer, Vol. 79, No. 7, 01.04.1997, p. 1362-1369.

Research output: Contribution to journalArticle

Gollamudi, SV, Gelman, RS, Peiro, G, Schneider, LJ, Schnitt, SJ, Recht, A, Silver, BJ, Harris, JR & Connolly, JL 1997, 'Breast-conserving therapy for Stage I-II synchronous bilateral breast carcinoma', Cancer, vol. 79, no. 7, pp. 1362-1369. https://doi.org/10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y
Gollamudi, Smitha Valli ; Gelman, Rebecca S. ; Peiro, Gloria ; Schneider, Lindsey J. ; Schnitt, Stuart J. ; Recht, Abram ; Silver, Barbara J. ; Harris, Jay R. ; Connolly, James L. / Breast-conserving therapy for Stage I-II synchronous bilateral breast carcinoma. In: Cancer. 1997 ; Vol. 79, No. 7. pp. 1362-1369.
@article{8ee2ca34f61448ca8b2b1e0d74a72108,
title = "Breast-conserving therapy for Stage I-II synchronous bilateral breast carcinoma",
abstract = "BACKGROUND. Synchronous bilateral breast carcinoma (SBBC) is an uncommon presentation, and the management of patients with this disease is not well established. METHODS. In order to evaluate whether patients with early-stage SBBC could be safely and effectively treated with bilateral breast-conserving therapy (BCT), the authors retrospectively reviewed the records of 24 patients with clinical Stage I-II SBBC treated during the period 1977-1989 with bilateral BCT. SBBC was defined as bilateral invasive carcinomas diagnosed no more than 1 month apart. The median age at diagnosis was 56 years (range, 32-85-years), and the median follow-up for surviving patients was 95 months (range, 68-157 months). Pathology slides were available for review in 19 cases. Cosmetic results and complications after BCT were scored. Outcome was compared with that of 1314 patients with unilateral Stage I or II breast carcinoma, within the same age range, treated during the same time period. RESULTS. There were no significant differences between the SBBC and unilateral groups in actuarial disease free survival (70{\%} and 74{\%}, respectively, at 5 years), overall survival (88{\%} and 87{\%}, respectively, at 5 years), or crude distribution of sites of first failure. Multivariate analysis of overall survival and disease free survival also did not show bilaterality to be a significant factor. The cosmetic results for the SBBC group were not significantly different from those for the unilateral group. Physician assessment of cosmetic outcome was excellent in 57{\%} and good in 43{\%} of SBBC patients evaluated 25-48 months after BCT. Long term complications were rare in both groups. CONCLUSIONS. Patients with early-stage SBBC can be safely treated with carefully planned, bilateral BCT, with outcome that appears to be comparable to that of patients with early-stage unilateral breast carcinoma.",
keywords = "adenocarcinoma, bilateral, breast neoplasms, radiotherapy, synchronous",
author = "Gollamudi, {Smitha Valli} and Gelman, {Rebecca S.} and Gloria Peiro and Schneider, {Lindsey J.} and Schnitt, {Stuart J.} and Abram Recht and Silver, {Barbara J.} and Harris, {Jay R.} and Connolly, {James L.}",
year = "1997",
month = "4",
day = "1",
doi = "10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y",
language = "English (US)",
volume = "79",
pages = "1362--1369",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Breast-conserving therapy for Stage I-II synchronous bilateral breast carcinoma

AU - Gollamudi, Smitha Valli

AU - Gelman, Rebecca S.

AU - Peiro, Gloria

AU - Schneider, Lindsey J.

AU - Schnitt, Stuart J.

AU - Recht, Abram

AU - Silver, Barbara J.

AU - Harris, Jay R.

AU - Connolly, James L.

PY - 1997/4/1

Y1 - 1997/4/1

N2 - BACKGROUND. Synchronous bilateral breast carcinoma (SBBC) is an uncommon presentation, and the management of patients with this disease is not well established. METHODS. In order to evaluate whether patients with early-stage SBBC could be safely and effectively treated with bilateral breast-conserving therapy (BCT), the authors retrospectively reviewed the records of 24 patients with clinical Stage I-II SBBC treated during the period 1977-1989 with bilateral BCT. SBBC was defined as bilateral invasive carcinomas diagnosed no more than 1 month apart. The median age at diagnosis was 56 years (range, 32-85-years), and the median follow-up for surviving patients was 95 months (range, 68-157 months). Pathology slides were available for review in 19 cases. Cosmetic results and complications after BCT were scored. Outcome was compared with that of 1314 patients with unilateral Stage I or II breast carcinoma, within the same age range, treated during the same time period. RESULTS. There were no significant differences between the SBBC and unilateral groups in actuarial disease free survival (70% and 74%, respectively, at 5 years), overall survival (88% and 87%, respectively, at 5 years), or crude distribution of sites of first failure. Multivariate analysis of overall survival and disease free survival also did not show bilaterality to be a significant factor. The cosmetic results for the SBBC group were not significantly different from those for the unilateral group. Physician assessment of cosmetic outcome was excellent in 57% and good in 43% of SBBC patients evaluated 25-48 months after BCT. Long term complications were rare in both groups. CONCLUSIONS. Patients with early-stage SBBC can be safely treated with carefully planned, bilateral BCT, with outcome that appears to be comparable to that of patients with early-stage unilateral breast carcinoma.

AB - BACKGROUND. Synchronous bilateral breast carcinoma (SBBC) is an uncommon presentation, and the management of patients with this disease is not well established. METHODS. In order to evaluate whether patients with early-stage SBBC could be safely and effectively treated with bilateral breast-conserving therapy (BCT), the authors retrospectively reviewed the records of 24 patients with clinical Stage I-II SBBC treated during the period 1977-1989 with bilateral BCT. SBBC was defined as bilateral invasive carcinomas diagnosed no more than 1 month apart. The median age at diagnosis was 56 years (range, 32-85-years), and the median follow-up for surviving patients was 95 months (range, 68-157 months). Pathology slides were available for review in 19 cases. Cosmetic results and complications after BCT were scored. Outcome was compared with that of 1314 patients with unilateral Stage I or II breast carcinoma, within the same age range, treated during the same time period. RESULTS. There were no significant differences between the SBBC and unilateral groups in actuarial disease free survival (70% and 74%, respectively, at 5 years), overall survival (88% and 87%, respectively, at 5 years), or crude distribution of sites of first failure. Multivariate analysis of overall survival and disease free survival also did not show bilaterality to be a significant factor. The cosmetic results for the SBBC group were not significantly different from those for the unilateral group. Physician assessment of cosmetic outcome was excellent in 57% and good in 43% of SBBC patients evaluated 25-48 months after BCT. Long term complications were rare in both groups. CONCLUSIONS. Patients with early-stage SBBC can be safely treated with carefully planned, bilateral BCT, with outcome that appears to be comparable to that of patients with early-stage unilateral breast carcinoma.

KW - adenocarcinoma

KW - bilateral

KW - breast neoplasms

KW - radiotherapy

KW - synchronous

UR - http://www.scopus.com/inward/record.url?scp=0030955021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030955021&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y

DO - 10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y

M3 - Article

C2 - 9083159

AN - SCOPUS:0030955021

VL - 79

SP - 1362

EP - 1369

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -